Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies.

Autor: Tiwari P; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India; Jawaharlal Nehru University, New Delhi, India., Shukla RP; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Yadav K; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Panwar D; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Agarwal N; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Kumar A; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Singh N; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Bakshi AK; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Marwaha D; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Gautam S; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Rai N; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India., Mishra PR; Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute Lucknow, India; Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, U.P., India. Electronic address: prabhat_mishra@cdri.res.in.
Jazyk: angličtina
Zdroj: Journal of molecular graphics & modelling [J Mol Graph Model] 2024 May; Vol. 128, pp. 108702. Date of Electronic Publication: 2024 Jan 03.
DOI: 10.1016/j.jmgm.2024.108702
Abstrakt: In recent years, Onco-immunotherapies (OIMTs) have been shown to be a potential therapy option for cancer. Several immunotherapies have received regulatory approval, while many others are now undergoing clinical testing or are in the early stages of development. Despite this progress, a large number of challenges to the broad use of immunotherapies to treat cancer persists. To make immunotherapy more useful as a treatment while reducing its potentially harmful side effects, we need to know more about how to improve response rates to different types of immunotherapies. Nanocarriers (NCs) have the potential to harness immunotherapies efficiently, enhance the efficiency of these treatments, and reduce the severe adverse reactions that are associated with them. This article discusses the necessity to incorporate nanomedicines in OIMTs and the challenges we confront with current anti-OIMT approaches. In addition, it examines the most important considerations for building nanomedicines for OIMT, which may improve upon current immunotherapy methods. Finally, it highlights the applications and future scenarios of using nanotechnology.
Competing Interests: Declaration of competing interest None.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: